"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 4 | 1 | 5 |
| 2001 | 2 | 5 | 7 |
| 2002 | 2 | 0 | 2 |
| 2003 | 0 | 3 | 3 |
| 2004 | 1 | 4 | 5 |
| 2005 | 1 | 6 | 7 |
| 2006 | 4 | 0 | 4 |
| 2007 | 4 | 4 | 8 |
| 2008 | 5 | 2 | 7 |
| 2009 | 8 | 3 | 11 |
| 2010 | 12 | 5 | 17 |
| 2011 | 10 | 2 | 12 |
| 2012 | 6 | 5 | 11 |
| 2013 | 5 | 4 | 9 |
| 2014 | 6 | 3 | 9 |
| 2015 | 7 | 2 | 9 |
| 2016 | 8 | 6 | 14 |
| 2017 | 3 | 6 | 9 |
| 2018 | 6 | 6 | 12 |
| 2019 | 0 | 6 | 6 |
| 2020 | 4 | 5 | 9 |
| 2021 | 6 | 8 | 14 |
| 2022 | 0 | 6 | 6 |
| 2023 | 2 | 0 | 2 |
| 2024 | 6 | 3 | 9 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. Cancer Med. 2025 Apr; 14(7):e70549.
-
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025 Feb; 10(2):138-153.
-
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct; 8:e2400477.
-
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
-
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. J Clin Oncol. 2024 Sep 01; 42(25):3033-3046.
-
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul; 8:e2400219.
-
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Breast Cancer Res. 2024 Jun 07; 26(1):95.
-
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. J Clin Oncol. 2024 Aug 20; 42(24):2918-2927.
-
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2024 Apr; 8:e2300527.
-
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):265-270.